by Francesco Zangari | Apr 8, 2021
From the H1N1 pandemic of 2009, Canada recognized it was not ready for a pandemic. “What we were not prepared for was for the pandemic to occur when it did,” said an interviewee at a panel review of Canada’s response to the 2009 H1N1 pandemic. “So, it...
by Jovana Drinjakovic | Sep 9, 2020
In 2015, Jason Moffat walked into Sheila Singh’s office at McMaster University and gave her a small vial of clear liquid. The vial contained ten milliliters, or two teaspoons, of an injectable antibody, created in Moffat’s lab in Toronto, with a street value of around...
by Tara Fernandez | Aug 26, 2020
Regenerative medicines could have life-saving potential by dampening inflammation The COVID-19 pandemic is one of modern medicine’s greatest challenges. There have been 20 million (and counting) confirmed cases worldwide and, if predictions are right, the worst is yet...
by Sara M. Nolte | Feb 14, 2020
We’ve spent a lot of time swooning over CAR T-cells and CRISPR here at Signals, but recently a potential up-and-coming leading lady in the gene and cancer therapy fields has caught our eye. Our interest was piqued by a recent press release from The Max Delbruck Center...
by Tara Fernandez | Oct 17, 2019
RNA-based vaccines have been heralded as a new molecular weapon in the arsenal against cancer and infections. Five years ago, they were thrust into the spotlight following a $52 million investment by the Bill and Melinda Gates Foundation to CureVac, a...
Comments